Abstract-For triage purposes following a nuclear accident, bloodbased gene expression biomarkers can provide rapid dose estimates for a large number of individuals. Ionizing-radiation-responsive genes are regulated through the DNA damage-response pathway, which includes activation of multiple transcription factors. Modulators of this pathway could potentially affect the response of these biomarkers and consequently compromise accurate dose estimation calculations. In the present study, four potential confounding factors were selected: cancer condition, sex, simulated bacterial infection (lipopolysaccharide), and curcumin, an anti-inflammatory/ antioxidant agent. Their potential influence on the transcriptional response to radiation of the genes CCNG1 and PHPT1, two biomarkers of radiation exposure ex vivo, was assessed. First, both CCNG1 and PHPT1 were detected in vivo in blood samples from radiotherapy patients and as such were validated as biomarkers of exposure. Importantly, their basal expression level was slightly but significantly affected in vivo by patients' cancer condition. Moreover, lipopolysaccharide stimulation of blood irradiated ex vivo led to a significant modification of CCNG1 and PHPT1 transcriptional response in a dose-and time-dependent manner with opposite regulatory effects. Curcumin also affected CCNG1 and PHPT1 transcriptional response counteracting some of the radiation induction. No differences were observed based on sex. Dose estimations calculated using linear regression were affected by lipopolysaccharide and curcumin. In conclusion, several confounding factors tested in this study can indeed modulate the transcriptional response of CCNG1 and PHPT1 and consequently can affect radiation exposure dose estimations but not to a level which should prevent the biomarkers' use for triage purposes.
INTRODUCTION
GENE EXPRESSION biomarkers are of great interest as potential bioindicators to determine radiation exposure and dose received (Kabacik et al. 2011a and b; Budworth et al. 2012; Manning et al. 2013; Kabacik et al. 2015; Badie et al. 2016; Manning et al. 2017b ). The amount of mRNA of specific genes involved in DNA damage-response (DDR) (Kabacik et al. 2011a; Manning et al. 2013 ) as well as noncoding RNA (Kabacik et al. 2015) has been proven to show a strong dose-response relationship in blood irradiated ex vivo, making them of great interest for biological dosimetry purposes. In case of emergency, gene expression analysis could offer the advantage of providing quicker results and larger-scale analysis compared to other classic assays like dicentric or micronucleus assays (Pernot et al. 2012; Rothkamm et al. 2013; Hall et al. 2017) , and this has been successfully tested in exercises with dose assessments of coded samples Abend et al. 2016; Manning et al. 2017a) .
Ionizing radiation (IR) induces genotoxic lesions that activate the transcription of genes involved in cell death, DNA repair, cell cycle arrest, and autophagy. The induction of these genes involves the recognition of the DNA damage by the kinases ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR), which phosphorylate and activate transcription factors responsible for inducing mRNA expression (Christmann and Kaina 2013) . The main transcription factors regulated by DDR are p53, nuclear factor kappa B (NF-kappaB), breast cancerassociated protein 1 (BRCA1), and AP-1 (Christmann and Kaina 2013) . The transcription factor p53 plays a major role in activating the transcription of target genes involved in DDR and is the principal mediator of senescence, apoptosis, and cell cycle arrest (Toledo and Wahl 2006; Christmann and Kaina 2013) . Inflammatory and anti-inflammatory mediators have been identified to modulate p53 at a transcriptional level (Choudhuri et al. 2002; Li et al. 2015; Odkhuu et al. 2015) , which could consequently affect its downstream target genes during DDR. For instance, transcriptional responses to radiation of p53-dependent genes such as MDM2, BBC3, FDXR, and CDKN1A have been shown to be affected in the presence of confounding factors such as lipopolysaccharide (LPS) and curcumin (Budworth et al. 2012; Soltani et al. 2016) .
Cyclin G1 (CCNG1) and phosphohistidine phosphatase 1 (PHPT1) are both downstream genes of the transcription factors activated through DDR and have been identified as genes responsive to IR in whole human blood and in peripheral blood lymphocytes irradiated ex vivo (Paul and Amundson 2008; Kabacik et al. 2011b; Manning et al. 2013) . Ex vivo analysis of CCNG1 and PHPT1 responsiveness to radiation has shown low interindividual variability in their transcriptional response to radiation, and a linear dose response at low doses (25-100 mGy) for CCNG1 and high doses (1-4 Gy) for PHPT1 (Manning et al. 2013) , providing high accuracy for estimating the dose received and making them potential biomarkers of IR exposure in vivo. To be able to provide accurate and reproducible dose estimation using transcriptional markers, the influence of confounding factors, which could affect DDR pathways and might modulate their responses, should be taken into consideration. In the present study this important issue was addressed by studying the response of CCNG1 and PHPT1 to several confounding factors potentially able to modulate their radiationinduced transcriptional response. First, the radiation response of these genes was assessed in vivo in blood from cancer patients treated with radiation therapy in order to validate them for biological dosimetry purposes. Then, cancer condition, simulation of bacterial infection with LPS, and the use of an anti-inflammatory agent (curcumin) were tested as potential confounding factors affecting these biomarkers' response to radiation. The findings indicated that both CCNG1 and PHPT1 are radiation responsive in vivo. The ex vivo assessment found that confounding factors can modify the biomarkers' expression and consequently could affect estimation of dose but to an extent that should not affect the biomarkers' use in biodosimetry.
MATERIALS AND METHODS

Blood collection and irradiation ex vivo
Peripheral blood samples freshly collected from 10 healthy donors (5 men and 5 women; age range: 35-60 y) were incubated with two different concentrations of LPS (1 ng mL
and 500 ng mL −1 ) or curcumin (15 mM) (Sigma-Aldrich, 2nd Av., Heatherhouse Industrial Estate, Irvine KA12 8NB, UK). LPS and curcumin were added to 500 mL of blood (1) 1 h before being either mock irradiated or exposed to a 2 Gy x-ray dose (0.5 Gy min −1 ) or (2) just after exposure (LPS only). A Harmonized System (HS) x-ray system (AGO X-Ray Ltd., Aldermaston, Reading RG7 4PW, UK) (output 13 mA, 250 kV peak) was used to irradiate the samples. Blood samples were kept at 37°C in an incubator with 5% CO 2 for either 2 h or 24 h after exposure. After the incubation time, the blood was mixed with 1 mL of RNAlater (Fisher Scientific UK, Bishop Meadow Rd., Loughborough LE11 5RG, UK) and stored at −80°C until being processed for RNA extraction. Venous blood was taken at the Centre for Radiation, Chemical, and Environmental Hazards Public Health England (Chilton, UK) with informed consent and the ethical approval of the West Midlands-Solihull Research Ethics Committee (study approval number REC 14/WM/1182).
In an independent experiment, peripheral blood from five healthy donors, purchased from the French Blood Bank (Etablissement Français du Sang, 29 Avenue Maquis du Grésivaudan, 38700 La Tronche, France) under contract #15-2041, was exposed to a range of gamma-irradiation doses ( 60 Co source, doses of 50 mGy, 100 mGy, 2 Gy, and 4 Gy with a dose rate of 0.038 Gy min −1 or 1.47 Gy min
for doses below and above 1 Gy, respectively). Blood samples were incubated at 37°C in an incubator with 5% CO 2 . One hour after irradiation, 1 ng mL −1 of LPS was added and the RNA was isolated 2 h later.
Radiotherapy patient samples
Blood samples from four breast, two endometrial, one prostate, and two lung cancer patients (age range: 36-86 y) treated with intensity modulated radiotherapy (IMRT) using a linear accelerator (LINAC) were collected at five different time points during the course of the treatment: before the start of the treatment, 0.5-2 h and 24 h after the first fraction, just before the fifth or sixth fraction, and at the last fraction. For the last two time points, the blood was collected 21-28 h after the previous fraction. The prescribed doses for each patient are described in Table 1 . Patients did not receive previous radio-and/or chemotherapy treatments except for one of the lung cancer patients who received chemotherapy five weeks before the start of radiotherapy. Blood was collected at the Royal Marsden Hospital and Institute of Cancer Research (Surrey, UK) and was taken with written informed consent from all subjects and the ethical approval by the Health Research Authority (study approval number REC 16/SC/0307).
Another three subgroups of patients were recruited, including seven head and neck squamous cell carcinoma (HNSCC) and six prostate cancer (PC) patients treated with IMRT using a LINAC, and nine PC patients treated with stereotactic ablative radiotherapy (SABR) using a CyberKnife (CK) treatment unit (patients had no previous surgery or chemotherapy). Patient ages ranged from 52 to 75 y. The blood collection times, dose rates, dose per fraction, and total dose received are listed in Table 2 . The blood was collected between 1-18 h after the fifth and seventh fractions and after 1-2 h after the last fraction. Blood was collected at the Maria Sklodowska-Curie Institute Oncology Center (Gliwice, Poland). This study was carried out in accordance with the Bioethical Committee in Maria Sklodowska-Curie Institute, Warszaw, approval number 27/2015 from 18 August 2015.
Blood samples from all different patient groups were collected in PAXgene tubes according to the manufacturer's protocol (QIAGEN, PreAnalytiX GmbH, QIAGEN Str 1, 40724 Hilden, Germany).
Blood from 20 healthy donors (8 men and 12 women, ages ranging from 25 to 60 y) was also collected at the Centre for Radiation, Chemical, and Environmental Hazards Public Health England (Chilton, UK) in PAXgene tubes to compare the basal expression levels of the target genes from healthy donors and cancer patients.
RNA isolation and reverse transcription
Total RNA from blood samples exposed ex vivo to x rays was extracted using a RiboPure-Blood RNA Purification Kit (Fisher Scientific). Total RNA from samples collected in PAXgene tubes from radiotherapy patients was extracted with the PAXgene Blood miRNA Kit (QIAGEN, Germany) using a robotic workstation Qiacube (QIAGEN, Skelton House, Lloyd St., N., Manchester M15 6SH, UK). The quantity of isolated RNA was determined by spectrophotometry with an ND-1000 NanoDrop (Thermo Fisher Scientific, 168 3rd Av., Waltham, MA 02451 USA) and quality was assessed using a Tapestation 220 (Agilent Technologies, 5301 Stevens Creek Blvd., Santa Clara, CA 95051 USA). cDNA was prepared from 350 ng of the total RNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 850 Lincoln Centre Dr., Foster City, CA 94404 USA) according to the manufacturer's protocol.
For samples exposed to gamma radiation, total RNA was extracted from 400 mL of whole blood with a Nucleospin RNA Blood Kit (Macherey Nagel, 1 Rue Gutenberg, 67720 Hoerdt, France) according to the manufacturer's instructions. RNA was converted into cDNA using an Enhanced Avian HS RT-PCR Kit (Sigma-Aldrich, Lyon-Saint Exupéry BP 113, 69125 Lyon, France) with oligo-dT priming according to the manufacturer's protocol.
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (QRT-PCR) was performed using a Rotor-Gene Q (QIAGEN, Hilden, Germany) with PerfeCTa MultiPlex qPCR SuperMix (Quanta Bioscience, Inc., 202 Perry Parkway, Suite 1, Gaithersburg, MD 20877 USA). The samples were run in triplicate in 10 mL reactions with 1 mL of the cDNA synthesis ) gave PCR efficiencies between 93 and 103% for each gene with R 2 > 0.998. For samples exposed to gamma irradiation, SYBRGreen qPCR was performed using the LuminoCt SYBR Green qPCR ReadyMix (Sigma-Aldrich, Lyon, France) in triplicate 10 mL reactions containing 2 mM primers and 2 mL of cDNA diluted one-twentieth in water in the following conditions: 20 s at 95°C, then 40 cycles of 5 s at 95°C and 20 s at 60°C on a CFX 384 Real Time System thermal cycler (Bio-Rad, 3 Boulevard Raymond Poincaré, 92430 Marne-la-Coquette, France). Data were collected and analyzed with the CFX Manager 3.1 Software (Bio-Rad). Gene target Ct values were normalized to ribosomal protein lateral stalk subunit P0 (36B4) and HPRT1 internal controls. Primers for these targets were: 36B4 sens: 5' GAAATCCTGGGTGTCCGCAATGTT 3', rev: 5' AGACAAGGCCAGGACTCGTTTGTA 3'; HPRT1 sens: 5' ATGGACAGGACTGAACGTCTTGCT 3', rev: 5' TTGAGCACACAGAGGGCTACAATG 3'. Amplification efficiency of these primer pairs were 100.1% for HPRT1 and 98% for 36B4.
Dose estimation curve
Blood from 10 healthy donors (5 men and 5 women; age range: 35-60 y) was collected and exposed to a range of x-ray doses (0.25, 0.5, 1, and 2 Gy at a dose rate of 0.5 Gy min −1 ) and after 24 h, RNA was extracted using a RiboPure-Blood RNA Purification Kit (Fisher Scientific, Loughborough, UK) and the cDNA synthesized using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The cDNA from the 10 donors was combined and used as a calibration curve in each multiplexed QRT-PCR run to estimate the dose to the blood samples stimulated with LPS and curcumin as previously described (Manning et al. 2013) . A linear fit was used to construct the dose estimation curve, and the increase in expression following irradiation for each sample was entered into the linear equation to give a dose estimate.
Statistical analysis
Statistical analyses were performed using Minitab software (Minitab Inc., Quality Plaza, 1829 Pine Hall Rd., State College, PA 16801 USA). Data are presented as means ± standard deviation (SD). Comparisons were analyzed by an unpaired t-test (Student's t-test) or a paired t-test. A significance of p ≤ 0.05 was applied to all statistical tests performed. Statistical analyses were performed in log-transformed data.
RESULTS
Gene expression dose response of CCNG1 and PHPT1
The gene expression profile of CCNG1 and PHPT1 in blood exposed ex vivo to doses ranging from 0.25 to 4 Gy was monitored at 24 h postexposure ( Fig. 1a and b) . The results showed a dose-dependent up regulation of transcription which reached a plateau phase for doses above 1 Gy for CCNG1 and 3 Gy for PHPT1. When comparing both dose-response curves (Fig. 1c) , a higher response to radiation can be seen with PHPT1 than CCNG1 for all the different doses.
Basal CCNG1and PHPT1 expression levels in vivo: Healthy donors and cancer patients Comparisons between healthy donors and cancer patients were performed in order to see if cancer itself may be a confounding factor by modifying CCNG1 and PHPT1 basal expression levels (Fig. 2 ). CCNG1 and PHPT1 expression level in peripheral blood from 20 healthy donors (12 women and 8 men) was compared to 31 cancer patients (7 head and neck, 16 prostate, 4 breast, 2 lung, and 2 endometrial cancer patients). Interestingly, the results indicate a significantly lower basal expression level for CCNG1 in cancer patients; conversely, a significantly increased PHPT1 expression in cancer patients compared to healthy donors was observed.
Gene expression profile of CCNG1 and PHPT1 in vivo: Cancer patients during radiation therapy
The gene expression profile of CCNG1 and PHPT1 was analyzed in peripheral blood from cancer patients treated with different external-beam radiotherapy regimens for different cancer types. Two independent studies on separate cohorts were performed in which blood was collected at different points during the treatment.
In the first study, peripheral blood from nine patients was collected at five different time points during the course of the radiotherapy treatment (Table 1) . When the data for all patients were analyzed together (Fig. 3a) , CCNG1 showed a significant up regulation of expression in vivo at all time points, peaking before the fifth and sixth fraction. Similar CCNG1 expression profiles were observed in each cancer group analyzed individually (Fig. 3b-e) . Interestingly, PHPT1 shows a different expression profile with a significant drop in gene expression shortly after the first fraction (0.5-2 h) and before the last fraction (Fig. 3f ) . Similar to CCNG1, PHPT1 also showed an up regulation at the third sampling point, 24 h after the first fraction. Looking at each individual cancer type, PHPT1 shows a very similar pattern of expression along the sampling time points during the radiation therapy (Fig. 3g-j) .
The second study included 22 cancer patients treated with IMRT or SABR. Peripheral blood from these patients was collected before the start of the treatment, after one to seven fractions and at the end of the treatment (Table 2) . For this cohort, samples were also collected one month ). The expression profile of these genes has been compared in (c) using the mean ± SD of the 10 donors (c). Fig. 2 . Range of basal gene expression levels of CCNG1 and PHPT1 in healthy donors (8 men and 12 women, ages ranging from 25 to 60 years) and cancer patients (head and neck, prostate, breast, endometrial, and lung cancer, ages ranging from 36 to 86 years). The data is presented as individual data points together with the mean ± SD (n = 20 for the healthy donors group and n = 31 for the cancer patients group). Statistical analyses were performed on log-transformed data. Asterisk (*) indicates statistically significant differences with the healthy donors group (t-test, p ≤ 0.05).
following the end of the treatment allowing assessment of the duration of the radiation-induced transcriptional changes. The results showed a similar profile for CCNG1 and PHPT1 in each group. Both genes were up regulated in the IMRT groups after the first, fifth, and seventh fractions (Fig. 4) , but whereas PHPT1 stayed up regulated at the end of the treatment in the HNSCC patients, CCNG1 did not. In the same group, CCNG1 showed a decrease in expression one month after the last fraction was received. The same profile was observed in the SABR PC group where both biomarkers were up regulated at the end of the treatment (after fifth and last fraction) corresponding more closely to the second time point in the IMRT groups. Apart for the down regulation of CCNG1 in the HNSCC group, the expression level of both genes went back to basal level one month after the last fraction. Fig. 3 . Expression levels of CCNG1 and PHPT1 mRNA relative to HPRT1 in blood from four breast, two endometrial, one prostrate, and two lung cancer patients treated with IMRT. Blood was collected at five time points: (1) before the start of the treatment, (2) 0.5-2 h and (3) 24 h after the first fraction, (4) before the fifth or sixth fraction, and (5) before last fractions. Data are shown as individual data points for all patients together with the mean ± SD (a and f ). Each individual cancer group is also represented (b, c, d, e and g, h, i, j) . Statistical analyses were performed on logtransformed data. Significant differences (paired t-test, p ≤ 0.05) with the control (blood collection point 1) are indicated with an asterisk (*). Fig. 4 . Gene expression of CCNG1 and PHPT1 in blood from HNSCC as well as PC patients treated with IMRT and PC patients treated with SABR. Blood was collected before the start of the treatment (A), after 5/7 fractions for the IMRT groups and after the first fraction for the SABR group (B), after the last fraction (C), and 1 month after the last fraction (D). Data are shown as individual data points together with the mean ± SD (n = 7 for HNSCC, n = 6 for prostate-IMRT, and n = 9 for prostate-CK). Statistical analyses were performed on log-transformed data. Significant differences (paired t-test, p ≤ 0.05) with the control (blood collection point A) are indicated with an asterisk (*).
Effect of LPS and curcumin on CCNG1 and PHPT1 gene expression in response to ionizing radiation
The effect of two other potential confounding factors was assessed in peripheral blood from healthy donors exposed ex vivo to IR.
LPS modulated the transcription of CCNG1 and PHPT1 with a different regulatory effect in a time-dependent manner. CCNG1 showed a significant LPS dose-dependent down regulation at 2 h. This LPS effect was also observed when the blood was exposed to 2 Gy, and LPS counteracted the radiation induction of CCNG1 expression (Fig. 5a ). The administration of LPS before and/or just after irradiation showed the same down regulatory effect on CCNG1 expression (Fig. 5a) . However, after 24 h postirradiation, the effect of LPS on CCNG1 expression was not detected, irrespective of the irradiation status (Fig. 5b) .
On the contrary, PHPT1 showed an opposite regulation by LPS. PHPT1 was up regulated by LPS at 2 h postexposure in nonirradiated samples for the highest concentration of LPS (500 ng mL −1 ) (Fig. 5c) . After 24 h, the LPS effect was persistent in nonirradiated samples showing a clear dose dependency (Fig. 5d) . In irradiated samples at 24 h, LPS showed a costimulatory effect with irradiation, inducing a higher transcriptional response than the one observed with irradiation alone (Fig. 5d) .
The effect of LPS (1 ng mL
) was also tested when administered 1 h after exposure to a range of gamma-radiation doses (50 mGy, 100 mGy, 2 Gy, and 4 Gy) and gene expression of CCNG1 and PHPT1 was analyzed 2 h postirradiation. The results indicated that CCNG1 responds to low doses delivered at a lower dose rate (50 mGy, 100 mGy at 0.038 Gy min −1 ) but PHPT1 does not (Fig. 6 ). For CCNG1, LPS added 1 h after blood irradiation had a down-regulatory effect on its response to IR, as observed when added before irradiation (Fig. 5a ) but with a slighter effect. Significant differences between irradiated samples and irradiated samples in the presence of LPS were observed only at the lowest 50 mGy dose in the case of CCNG1 expression (Fig. 6a) . The late addition of LPS in blood didn't modulate further the response of PHPT1 to radiation (Fig. 6b) .
Curcumin exerted a similar regulatory effect on both genes but with different kinetics (Fig. 5) . Curcumin counteracted ) or curcumin (15 mM) 1 h before irradiation (2 Gy) or just after irradiation (only for LPS). Transcriptional expression of CCNG1 was analyzed at 2 h (a) and 24 h postirradiation (b) as well as for PHPT1 (c, d) . Data are shown as mean ± SD (n = 10, white symbols indicate 5 women and black symbols indicate 5 men). Statistical analyses were performed on log-transformed data. Significant differences (paired t-test, p ≤ 0.05) with the control are indicated with an asterisk (*) and differences with IR (only for IR groups) with a hash (#). the CCNG1 gene expression induced by irradiation at 24 h postexposure (Fig. 5b) . However, curcumin already modulated PHPT1 at 2 h postexposure (Fig. 5c) , showing a more pronounced effect at 24 h in the irradiated and nonirradiated blood samples (Fig. 5d) .
For some of the ex vivo experiments, five female donors and five male donors were used in order to assess the role of gender. No significant differences between males and females were found for CCNG1 or PHPT1 transcriptional response to IR, LPS, or curcumin alone or for IR with LPS or curcumin (Fig. 5) .
Modulation of dose estimation by confounding factors
A linear regression equation was calculated using the gene expression values of CCNG1 and PHPT1 obtained to construct a calibration curve. The calibration curve was performed by exposing blood from 10 healthy donors at a range of x-ray doses (0.25, 0.5, 1, and 2 Gy at 0.5 Gy min
−1
). The gene expression levels of CCNG1 and PHPT1 obtained in irradiated samples with LPS or curcumin were used to calculate the dose and assess how they can modify the estimated dose (Fig. 7) . The results indicated that LPS produces a modulation of the response to radiation at 24 h postexposure mainly for PHPT1 (Fig. 7b) . LPS lowers the radiation response of CCNG1 mainly at 2 h. At 24 h, LPS slightly affects CCNG1, exerting a not-very-pronounced underestimation of the dose compared to the effect of irradiation alone (Fig. 7a) . However, LPS induced a higher gene expression response to radiation in PHPT1 at 24 h, which translates to an overestimation of the dose received compared to irradiation alone (Fig. 7b) . Finally, the LPS effect observed is similar when LPS was administered 1 h before or just after irradiation. For curcumin, its presence in blood leads to a lower response of both genes to ionizing radiation at 24 h postexposure, thus leading to an underestimation of the dose calculations (Fig. 7a-b) .
DISCUSSION
In case of a radiation emergency after a nuclear accident, it is crucial to have a rapid and robust method to assess exposure to radiation and dose received for potentially large numbers of individuals in order to act accordingly (Kulka et al. 2017) . Gene expression has been proven to provide dose estimates in a short period of time and delivers consistent results from multiple institutions in several countries using different protocols for gene expression Abend et al. 2016; Manning et al. 2017a) . Genes regulated through DDR have been identified to be good gene expression biomarkers of radiation exposure ex vivo and are promising biomarkers for transcription-based biological dosimetry purposes Abend et al. 2016; Manning et al. 2017a) . Two genes, CCNG1 and PHPT1, were previously identified as showing strong responsiveness to radiation in experiments ex vivo (Manning et al. 2013) and were selected for this study. Their response to ionizing radiation ex vivo was confirmed by irradiating blood with a range of x-ray doses between 0.25 and 4 Gy (0.5 Gy min
−1
). PHPT1 showed a higher gene expression response to IR than CCNG1 as previously observed (Manning et al. 2013) . Interestingly, in gamma-irradiated blood at low doses (50 mGy and 100 mGy) at a lower dose rate (0.038 Gy min −1 ), CCNG1 (but not PHPT1) showed a significant response to radiation. This lack of PHPT1 response could be attributed to the low dose rate, since differences in response to dose and dose rates have been previously ) 1 h after exposure. The data is presented as individual data points together with the mean ± SD (n = 5). Asterisk (*) indicates significant differences with the control and hash (#) indicates significant differences with the irradiated control for the samples incubated with LPS (t-test, p ≤ 0.05).
observed between radiation-responsive genes (El-Saghire et al. 2013; Paul et al. 2013; Ghandhi et al. 2015) . The radiation source is unlikely to be the cause of those differences, although differences between x rays and gamma rays were previously reported for different endpoints (Janatpour et al. 2005; Scott et al. 2013 ). These differences in response to high and low dose rates may be of interest in order to determine a gene expression signature providing information on dose and dose rate.
Being able to validate the radiation responsiveness of CCNG1 and PHPT1 in vivo is paramount if they are to be considered as biomarkers for biological dosimetry purposes. In vivo expression profiles of both genes in patients with different types of cancer and treated with different radiotherapy regimens demonstrated that they are regulated after a partial-body exposure and thus are also good biomarkers of exposure in vivo. PHPT1 and CCNG1 have been previously determined to respond in blood from total-body irradiated patients (Filiano et al. 2011; Paul et al. 2011 ). Total-body irradiated patients received 1.25 Gy per fraction and three fractions per day (total dose of 3.75 Gy) (Paul et al. 2011) or 2 Gy twice a day for three consecutive days (total dose of 12 Gy) (Filiano et al. 2011) . Unlike totalbody irradiated patients, radiotherapy patients in the present study were partially exposed to treat their tumors and received a lower dose to the blood compared to total-body irradiated patients. Even under these partial-body irradiations and independently of the body localization of the radiation exposure (breast, endometrial, lung, or prostate), both PHPT1 and CCNG1 can be clearly detected above background expression levels in blood samples; this was also the case at different points during the course of the treatment. The main difference observed between total-and partial-body irradiation was the level of response. As expected, CCNG1 and PHPT1 showed a higher up regulation in total-body compared to partial-body patient irradiation.
In general, CCNG1 showed an increase in gene expression irrespectively of the cancer type (breast, lung, endometrium, prostate, or head and neck) after a short period of time after the first fraction (0.5 to 2 h time point) and also during and at the end of the radiotherapy treatment with cumulative doses in the range of 36.25 to 70 Gy. Although PHPT1 showed similar expression to the CCNG1 profile in the HNSCC and PC patients treated with IMRT and SABR (Fig. 4) after the first fractions (after the fifth and seventh fractions, first week of treatment approximately for IMRT and five fractions for SABR treatment), different responses were observed. PHPT1 presented a slightly higher expression response compared to CCNG1 at different points analyzed during the course of the radiation therapy in most of the cancer and treatment groups. PHPT1 showed an initial down regulation after a short period of time after radiation exposure (0.5-2 h), but its expression rose over the basal level significantly 24 h after the first fractions (Fig. 3 ). These differences in PHPT1 radiation response at different time points could be attributed to fluctuation patterns of expression after radiation exposure over time as previously observed in irradiated cultures of human T-lymphocytes in other genes also regulated through DDR (Kabacik et al. 2015) .
The expression of CCNG1 and PHPT1 was not significantly modified after one fraction in the SABR group (7.25 Gy) . Surprisingly, CCNG1 showed a lack of response in the HNSCC group at the end of the treatment, and this is also true for both genes in the group of PC patients treated with IMRT (Fig. 4) . As regulation of gene expression is a very dynamic and temporal process (Yosef and Regev 2011) , the high cumulative doses (78 Gy) and number of fractions in these particular groups could be responsible for an adaptation to the stimuli. Persistent stimulation over time could also be implicated in this lack of response or repression of expression. The expression level may also be affected by the modification of the white blood cells analyzed between the beginning and the end of the treatment; cell death, cell division, and cell renewal may change the global level of expression observed at different time points.
When comparing the expression profile of the cohorts studied here, differences in response were identified for PHPT1 after the first fractions and at the end of the treatment [before fifth and last fraction (Fig. 3f) and after fifth-seventh and last fraction (Fig. 4) ]. Transcriptional responses of genes regulated through DDR can be transient (Christmann and Kaina 2013) or can fluctuate over time (Kabacik et al. 2015) , so the time postexposure at which samples are analyzed has to be taken into consideration when comparing responses. Therefore, the differences observed between the two studies could be at least partially attributed to the blood collection time following several radiotherapy fractions; in the first group of patients, blood was collected later than the prescribed fraction dose (21-28 h after the fourth or fifth and the penultimate fraction) compared to the second group of patients [1-18 h after the fifth or seventh fraction and 1-3 h (not more than that) after last fraction].
When the basal expression level of these genes was compared to normal healthy donors, CCNG1 showed a significantly lower expression than the average of all the cancer patients. During cancer development there is dysregulation of cell functions and cell cycle control (Wiman and Zhivotovsky 2017) . Since cyclins are the main regulators of cell cycle transitions, it is not completely surprising that the basal CCNG1 expression level is modulated in cancer patients compared to a healthy population. On the contrary, PHPT1 showed a higher expression level in cancer patients than in healthy donors. These findings are very interesting, demonstrating the sensitivity of transcription to detect modifications in the body. In the context of this study, these differences in basal expression level could lead to inaccuracies in dose estimates when using these biomarkers. However, a relatively high variability can be seen within the cancer groups regarding the basal level of expression of these genes, and the altered basal expression level is patient dependent and applies only in specific cases. Moreover, the modifications of expression are small and would not affect dose estimates, at least based on the data from the cohort of patients studied.
This study then addressed the role of sex in the transcriptional response to ionizing radiation in blood samples exposed ex vivo. With the number of samples studied, it can be concluded that gender is not a confounding effect on the IR response of CCNG1 and PHPT1, or at least it is not a major one as no significant differences between males and females were detected irrespectively of the presence of LPS. Regarding the role of the age of the blood donors, there were not enough donors per age group to provide the statistical power needed to evaluate if age could be recognized as a potential confounding factor.
The effect of LPS and curcumin as potential confounding factors in the response of biomarkers to IR was analyzed in blood samples from 10 donors exposed ex vivo. Ex vivo experiments have been demonstrated to be an excellent model for identifying biomarkers of gene expression, as their responses are translated in in vivo human blood samples (Paul et al. 2011; Abend et al. 2016 ). Blood from healthy donors was irradiated and/or incubated with LPS or curcumin for 2 h or 24 h, and the transcriptional expression level of CCNG1 and PHPT1 was assessed. LPS is a component of the outer membrane of gram-negative bacteria (Schletter et al. 1995) , and it is used as an inflammatory stimulus to mimic bacterial infection. When LPS was present in blood before or just after blood irradiation, it modulated the response of both biomarkers, mainly counteracting the induction of expression mediated by IR for CCNG1 and conversely increasing the response to IR for PHPT1. Transcription factor p53 is a key factor in DDR, and LPS has been reported to down regulate its expression (Odkhuu et al. 2015) . As CCNG1 transcriptional response to IR is driven by p53, the negative regulation of p53 expression by LPS could be responsible for the lower response of CCNG1 to IR. Consistent with the present study, the confounding effect of LPS has been previously observed with radiation-responsive genes like CDKN1A, BBC3, and FDXR (Budworth et al. 2012) , all three having a p53-dependent transcriptional expression. LPS also affects other transcription factors regulated through DDR, such as NF-kappaB, by increasing its activity (Odkhuu et al. 2015) , which consecutively could suppress expression of genes dependent on p53 transcriptional activation due to the competition of both transcription factors for transcription coactivators (Webster and Perkins 1999) . The mechanisms by which PHPT1 is regulated through the DDR pathway are to the best of the authors' knowledge not known, but the modulation of expression by transcription factors driving PHPT1 expression might be influenced by LPS and thus might lead to the increased response to IR under LPS stimulation. Although for the purpose of this study, this effect was not characterized in more detail, the opposite regulation mediated by LPS on CCNG1 and PHPT1 transcriptional response to radiation suggests that LPS might modulate response through different pathways, and this would certainly deserve further investigation.
In order to characterize further the role of time in these effects, the role of LPS when it was administered 1 h postexposure to irradiation was also assessed; in this setting, it affected CCNG1 response to IR but not PHPT1. DNA repair (such as double-strand break repair) occurs extremely quickly and can be observed as early as minutes following irradiation (Badie et al. 1995) , and one hour after irradiation, transcription factors such as p53 are active and induce transcription of their downstream target genes; this has been shown for CCNG1 and other p53-dependent genes by Kabacik et al. (2015) . In this study, CCNG1 expression was modulated by the addition of LPS 1 h postexposure, which modulates the activity of the pathway by which CCNG1 is regulated when transcription is fully active. The late administration of LPS didn't affect PHPT1 response to radiation, possibly because the addition of LPS was too late to exert an effect on its transcriptional activation pathway. Overall, these results also support the idea that the effect of LPS in the response to radiation of both genes happens through different pathways. Interestingly, LPS could potentially be used to reveal specific geneactivation pathways following IR exposure.
The response of CCNG1 and PHPT1 to IR was also tested under the presence of the natural dietary polyphenol, curcumin. Curcumin has been associated with antioxidant, anticancer, anti-inflammatory, and antimicrobial properties (Hussain et al. 2017) . In the present study, curcumin counteracted the up regulation of CCNG1 and PHPT1 by IR, showing an earlier effect on PHPT1 than on CCNG1. This counteractive effect of IR by curcumin has been reported for CDNK1A and BBC3 (Soltani et al. 2016) . Transcription factors involved in DDR, like p53 and NF-kappaB, have been previously identified as targets of curcumin (Brennan and O'Neill 1998; Moos et al. 2004) , both presenting impairment of functions mediated by curcumin action. Since the response of CCNG1 and PHPT1 to IR depends on DDR pathways, it is not surprising that curcumin modified their responses to some extent.
Finally, this study sought to quantify the importance of these modifications on dose estimations, which is crucial for biological dosimetry purposes. In a previous study, the authors used a polynomial regression for the dose calibration curve as it fitted the dose response observed for different genes better (Manning et al. 2013) . However, in the present study, a linear regression offered a better fit than a nonlinear one for the effect of the confounding factors and was therefore used in order to obtain dose estimates. LPS mainly increased the response of PHPT1 to radiation, with the higher overestimation being seen at the highest concentration (calculated dose 2.15 Gy for LPS at 500 ng mL −1 while the calculated dose without LPS was found to be 1.59 Gy for a physical dose of 2 Gy delivered to the blood). Further research is ongoing to better fit the data and provide a better curve for the estimation of doses.
Nevertheless, using a linear regression, this study showed an effect, although mostly moderate, on the dose calculated when LPS and curcumin were present in the irradiated blood samples.
CONCLUSION
First, these data validated PHPT1 and CCNG1 as biomarkers of radiation exposure in vivo, and they should be considered as gene-expression-based biological dosimetry tools in future studies. Second, when dose assessments have to be provided in the context of infection/inflammation, in the presence of anti-inflammatory/antioxidant agents, or for cancer patients, it was shown that these factors can modulate the response of these transcriptional biomarkers and hence affect dose estimation calculations, although not to a level that should prevent the use of these genes for triage purposes. These findings highlight the fact that some confounding variables may need to be taken into consideration when estimating the dose received and that information on a known infection at sampling time should allow more accurate dose estimates.
